Stock 603520 ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Zhejiang Starry Pharmaceutical Co.,Ltd.

Equities

603520

CNE1000026N8

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-10 pm EDT 		5-day change 1st Jan Change
9.59 CNY +5.15% Intraday chart for Zhejiang Starry Pharmaceutical Co.,Ltd. +5.85% -31.89%
May. 29 Starry Pharma Gets China Nod for MRI Contrast Agent Injectable MT
May. 28 Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it has received CNY 934.979955 million in funding CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Starry Pharma Gets China Nod for MRI Contrast Agent Injectable
MT
Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it has received CNY 934.979955 million in funding
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hu Jinsheng agreed to acquire 36% stake in Xianju Juhe Financial Services Co., Ltd. from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 19.8 million.
CI
Shanghai Ddsome Laboratories Co., Ltd announced that it has received funding from Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang Starry Pharmaceutical Co.,Ltd.
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Shanghai Ddsome Laboratories Co., Ltd announced that it expects to receive CNY 28 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.
CI
Starry Pharma’s Generic X-Ray Contrast Agent Gets Marketing Approval
MT
Zhejiang Starry Pharma’s CFO Resigns
MT
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership.
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 2.05 billion in funding
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Zhejiang Zhumei Import and Export Group Co., Ltd agreed to acquire Zhejiang Xianju Thermal Power Co., Ltd from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 35 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603520 Stock
  4. News Zhejiang Starry Pharmaceutical Co.,Ltd.